Insider Buying: Sensus Healthcare (NASDAQ:SRTS) Director Acquires $96,656.16 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta bought 27,304 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was bought at an average price of $3.54 per share, for a total transaction of $96,656.16. Following the completion of the acquisition, the director directly owned 294,784 shares in the company, valued at approximately $1,043,535.36. The trade was a 10.21% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Eric Sachetta also recently made the following trade(s):

• On Friday, August 28th, Eric Sachetta bought 37,537 shares of Sensus Healthcare stock. The shares were bought at an average cost of $3.44 per share, with a total value of $129,127.28.
• On Thursday, August 27th, Eric Sachetta purchased 10,925 shares of Sensus Healthcare stock. The stock was bought at an average price of $3.18 per share, with a total value of $34,741.50.
• On Wednesday, August 26th, Eric Sachetta acquired 9,708 shares of Sensus Healthcare stock. The shares were bought at an average price of $3.29 per share, for a total transaction of $31,939.32.
• On Monday, August 24th, Eric Sachetta acquired 34,697 shares of Sensus Healthcare stock. The shares were purchased at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Trading Up 3.4%

Shares of SRTS traded up $0.12 during midday trading on Monday, hitting $3.64. The stock had a trading volume of 102,018 shares, compared to its average volume of 65,130. Sensus Healthcare, Inc. has a fifty-two week low of $2.66 and a fifty-two week high of $5.49. The business has a 50-day simple moving average of $3.05 and a two-hundred day simple moving average of $3.51. The firm has a market cap of $59.91 million, a P/E ratio of -3.87 and a beta of 1.10.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $4.60 million.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Citigroup reissued a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Lake Street Capital dropped their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sensus Healthcare has a consensus rating of “Moderate Buy” and an average price target of $5.83.

Institutional Trading of Sensus Healthcare

Institutional investors have recently bought and sold shares of the company. Greenline Wealth Management LLC acquired a new position in Sensus Healthcare in the 4th quarter worth about $513,000. North Star Investment Management Corp. acquired a new stake in shares of Sensus Healthcare during the 1st quarter valued at about $500,000. Rothschild Wealth LLC bought a new stake in shares of Sensus Healthcare in the 4th quarter valued at approximately $500,000. Pacific Ridge Capital Partners LLC grew its stake in shares of Sensus Healthcare by 21.8% in the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after buying an additional 125,245 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Sensus Healthcare in the second quarter worth approximately $303,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.